BMB Reports 2023; 56(10): 527-536
Structural studies of serotonin receptor family
Apeksha Parajulee & Kuglae Kim*
Department of Pharmacy, College of Pharmacy, Yonsei University, Incheon 21983, Korea
Correspondence to: Tel: +82-32-749-4530; Fax: +82-32-749-4105; E-mail:
Received: July 27, 2023; Revised: September 1, 2023; Accepted: September 25, 2023; Published online: October 11, 2023.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Serotonin receptors, also known as 5-HT receptors, belong to the G protein-coupled receptors (GPCRs) superfamily. They mediate the effects of serotonin, a neurotransmitter that plays a key role in a wide range of functions including mood regulation, cognition and appetite. The functions of serotonin are mediated by a family of 5-HT receptors including 12 GPCRs belonging to six major families: 5-HT1, 5-HT2, 5-HT4, 5-HT5, 5-HT6 and 5-HT7. Despite their distinct characteristics and functions, these receptors’ subtypes share common structural features and signaling mechanisms. Understanding the structure, functions and pharmacology of the serotonin receptor family is essential for unraveling the complexities of serotonin signaling and developing targeted therapeutics for neuropsychiatric disorders. However, developing drugs that selectively target specific receptor subtypes is challenging due to the structural similarities in their orthosteric binding sites. This review focuses on the recent advancements in the structural studies of 5-HT receptors, highlighting the key structural features of each subtype and shedding light on their potential as targets for mental health and neurological disorders (such as depression, anxiety, schizophrenia, and migraine) drugs.
Keywords: GPCR, Neurotransmitter, Orthosteric binding sites, Serotonin, Signaling mechanism

G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors in the human genome with more than 800 members. The general structure of the GPCRs consists of seven hydrophobic transmembrane (TM) domains connected by alternating extracellular and intracellular loops. The N-terminus is located on the extracellular side of the cell while the C-terminus is located on the intracellular side. There are five different classes of GPCRs in humans based on the sequence phylogeny of a conserved seven transmembrane domain (7TM): class A (rhodopsin), class B1 (secretin), class B2 (adhesion), class C (glutamate), and class F (frizzled/smoothed) (1-3). Upon ligand binding, GPCRs initiate the transmission of signals across the cell membrane, leading to intracellular responses through the activation of intracellular heterotrimeric G proteins, G protein-receptor kinases, arrestins and other signaling pathways (4).

Serotonin is a neurotransmitter responsible for modulating mood, cognition, perception, memory, sleep, appetite, anxiety, gut motility and blood clotting. It is primarily present in the central nervous system (CNS), gut and blood platelets (5). Its functions are mediated by a family of serotonin receptors (5-HTR), including 12 GPCRs, and one ligand-gated cation channel (Table 1). With the exception of 5-HT3R, which is a ligand-gated ion channel, all the other 5-HT receptors (5-HT1, 5-HT2, 5-HT4, 5-HT5, 5-HT6 and 5-HT7) are members of GPCRs superfamily. The human CNS contains all the serotonin receptors except 5-HT2BR (6). A comparison of human G-protein coupled 5-HT receptors’ sequences shows strong conservation, with 33 residues fully conserved and 27 residues conserved up to 80%. These conserved residues are primarily located in the regions of the receptors that participate in ligand binding and G-protein interaction. This conservation highlights the critical role of these regions in mediating ligand binding and facilitating the signaling process through G-protein coupling (7).

Studying the structure, functions and effects of serotonin receptors is essential for understanding how serotonin functions in the brain and developing treatments for mental health disorders such as depression, anxiety, schizophrenia, and migraines (8, 9). However, developing drugs that selectively target specific receptor subtypes is challenging due to the structural similarities in their orthosteric binding sites. There are ongoing extensive research efforts to elucidate the precise mechanisms of action of each receptor subtype and explore their potential as drug targets for improved management of mental health and neurological disorders. The goal of this review is to present a detailed summary of the current understanding of the serotonin receptors’ structure based on available studies. It will discuss the structural characteristics of different serotonin receptor subtypes, the binding sites for their ligands, G-protein interactions, and the changes that occur in their conformation when the receptors are activated.


The general architecture of 5-HT receptors follows the canonical class A GPCR structure characterized by an amino terminus located externally, seven TM helices with hydrophobic regions, three extracellular and three intracellular domains, and a carboxy terminus positioned intracellularly (4). Residues within the TM domains bind to the receptors, whereas the intracellular domains interact with various cytoplasmic proteins to initiate the downstream signaling pathways (10). Despite the TM domains being fairly comparable, with minor variations in tilt and twist, there is significant diversity observed in the loops, particularly in extracellular loop 2 (ECL2). The conserved residues are identified using the Ballesteros-Weinstein numbering system which serves as an indicator of the correct residue position in the transmembrane of the GPCR family (11). The 3D structures of all 12 serotonin receptors have been determined using X-ray crystallography and cryo-electron microscopy (cryo-EM) (Table 1 and Fig. 1).

The classification of 5-HT receptors can also be based on their coupling with specific G proteins (Table 1). For instance, the 5-HT1R and 5-HT5R subtypes couple with Gi/o protein, leading to the inhibition of adenylyl cyclase (AC) activity and a reduction in cyclic adenosine monophosphate (cAMP) levels (12). On the other hand, 5-HT2R couples with Gq/11 protein, stimulating phospholipase C, which leads to elevated levels of inositol triphosphate and calcium ions (Ca2+) (13). The 5-HT4, 5-HT6 and 5-HT7 receptors couple with the Gs protein to enhance AC activity and elevate cAMP levels. Notably, 5-HT4R can bind to both Gs and Gi proteins with preference for Gs over Gi. Each subtype has unique characteristics and functions, although they share common structural features and signaling mechanisms (14). Apart from the typical coupling with G proteins, GPCRs have been discovered to participate in alternative signaling pathways through the recruitment of arrestins which results in GPCR desensitization. GPCR desensitization involves GPCR kinases (GRKs) being recruited to the receptor, subsequently phosphorylating it, and then β-arrestin binding, which sterically hinders further G protein coupling and leads to desensitization (15). Biased signaling is usually observed in 5-HT2R, where certain ligands selectively activate specific signaling pathways (16, 17).


The 5-HT1 receptor subfamily comprises 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F receptor subtypes. The subtypes are predominantly inhibitory in nature and are involved in regulating neurotransmitter release and neuronal activity. The 5-HT1 receptors play a role in mood regulation, anxiety, pain perception and are a target for migraine, depression, and schizophrenia therapeutic agents (6). In particular, the 5-HT1AR regulates mood, anxiety, cognition, sleep and pain perception in the brain, making it a potential target for therapeutic agents for conditions such as mood disorders, anxiety, cognitive issues, sleep disorders, and chronic pain (18). The 5-HT1BR, found predominantly in the CNS and peripheral vasculature, regulates neurotransmitter release and vasoconstriction (19, 20). It shares high sequence homology (77% within the TM regions) with 5-HT1DR (21). They are associated with migraine physiology and are a primary target of antimigraine drugs (22). 5-HT1ER is primarily expressed in the hippocampus and hypothalamus. Similarly, 5-HT1FR is expressed in the cortical and hippocampal areas of the brain and acts as a target for antimigraine drugs (23).

Three structures of Gi-coupled 5-HT1AR have been reported; the apo state, bound to the ligand 5-HT, and bound to aripiprazole (Table 1, Fig. 1A). Intriguingly, all three structures feature a lipid molecule, phospholipid phosphatidylinositol 4-phosphate (PtdIns4P), found in the pocket created by TM3, TM6 and TM7 of the receptor along with the α5 helix of the Gi protein. PtdIns4P interacts with 5-HT1AR and Gαi, leading to enhanced G-protein coupling and GTPase activity. Consequently, acting as a positive allosteric modulator for the receptor, and playing a crucial role in regulatory function. Moreover, cholesterol molecules surrounding the TM domain shape the ligand-binding pocket, thereby influencing ligand specificity for aripiprazole. The unbound (apo) form of the 5-HT1AR closely resembles its structure when bound to 5-HT. Within the orthosteric binding pocket (OBP), three water molecules are positioned in a spatial arrangement similar to that of 5-HT. These water molecules have been shown to exhibit similarities to the polar functional groups of 5-HT, suggesting their potential role in activating the receptor (24).

The ergoline class of drugs although target 5-HT1A/1B/1D/1E/1F and 5-HT2A/2B/2C receptors, they exert their antimigraine effects through the activation of 5-HT1B, 5-HT1D and 5-HT1F receptors. Ergotamine primarily binds to the 5-HT receptor family with varying affinities, likely due to variations in the EBP, as OBP remains highly conserved. For instance, ergotamine-bound 5-HT1BR adopts a typical active state, regulating the usual pathway, while 5-HT2BR combines active and inactive features, showing strong β-arrestin signaling selectivity (16, 25). In a crystal structure, ergotamine and dihydroergotamine revealed a similar binding mode to the human 5-HT1BR. The ligands bind to the OBP located deep within the 7TM core and an extended binding pocket (EBP) near the extracellular loops (Fig. 1A). The ergoline scaffold of the ligand forms a salt bridge interaction with D1293.32 (superscripts indicate the Ballesteros-Weinstein numbering for GPCR residues) (11), which is present in all the 5-HT receptors. Additionally, a narrow hydrophobic cleft formed by the side chains of C1333.36, I1303.33, W3276.48, F3306.51 and F3316.52 tightly interacts with the nearly planar ergoline ring system (25). Compared to ergot, donitriptan, an agonist of 5-HT1BR, binds differently. It engages residues from helices 3, 5, 6 and 7, extending into the extracellular region where it interacts with helices 6 and 7 and ECL2 in the receptor’s binding pocket. Its binding primarily relies on van der Waals interactions and has limited polar interactions, resembling ergotamine’s mode of binding. However, donitriptan and ergotamine occupy opposite sides of the binding pocket, with distinct orientations of F3517.65 and M3376.58 accommodating these ligands (26). On the contrary, the inverse agonist methiothepin (MT) predominantly binds to the lower OBP and shows minimal interactions with the EBP residues, which accounts for its non-selectivity towards other members of the 5-HT receptor family. In comparison to agonist-bound structure, MT causes structural changes by pushing some key residues (W3276.48, F3306.50 and F3316.51) within the binding pocket, leading to an inward shift in TM6, a common feature in inactive GPCR structures (27).

A study of the structure of 5-HT1ER bound to BRL-54443, a selective agonist for 5-HT1ER and 5-HT1FR, highlighted the significance of the 6.55 residue in the ligand binding pocket by influencing receptor selectivity. In 5-HT1ER, E3116.55 forms an additional hydrogen bond with BRL-54443’s hydroxyl group, which is absent in 5-HT1AR and 5-HT1DR due to different amino acids at that position (Fig. 2A). This interaction, along with the presence of identical E3136.55 and K3126.54 residues in 5-HT1FR, explains why BRL-54443 exhibits selectivity towards both the 5-HT1ER and 5-HT1FR. However, the replacement of the hydroxyl group by the carboxamide group in 5-carboxamidotryptamine (5-CT) shows a higher affinity towards HT1A, HT1B and 5-HT1D receptors than 5-HT1E and 5-HT1F receptors supporting the role of residue 6.55 as the determinant of subtype selectivity (24).

Triptan, a class of anti-migraine drugs, caused vasoconstrictive side effects by targeting 5-HT1B and 5-HT1D receptors, prompting the development of lasmiditan, a more selective anti-migraine drug targeting 5-HT1FR (28). The cryo-EM structure of lasmiditan bound to the 5-HT1FR (Fig. 2A) revealed differences in the EBP unlike the 5-HT1BR, while the OBP remained conserved. Structural differences are also observed in the extracellular region, with TM4 and TM5 shifting away in the 5-HT1FR. Notably, lasmiditan interacts with E3136.55 and N3176.59 residues in the TM6 of 5-HT1FR through hydrogen bonds unlike the S3346.55 and P3386.59 in 5-HT1BR, which cannot form similar interactions. Similarly, lasmiditan interaction resulted in distinct conformations of ECL2 in both the 5-HT1F and 5-HT1B receptors. Despite its high sequence homology with 5-HT1ER, lasmiditan is selective for 5-HT1FR due to differences in TM4, TM5 and ECL2 conformations. These structural distinctions explain lasmiditan’s specificity for 5-HT1FR (29).


The 5-HT2 receptor family consists of 5-HT2A, 5-HT2B and 5-HT2C subtypes. Although primarily Gq/11-coupled, 5-HT2AR and 5-HT2BR also recruit β-arrestin-2 upon lysergic acid diethylamide (LSD) and ergotamine binding. These receptors are widely distributed in the brain and peripheral tissues, with 5-HT2AR contributing to vascular tone regulation, mood, cognition and hallucinogenic effects. Selective modulation of 5-HT2AR is a potential treatment option for various neuropsychiatric conditions and neurological disorders (30). 5-HT2BR are found in the smooth muscle cells, cardiac tissue and endothelial cells, playing a role in cardiovascular function. 5-HT2CR are present in the gastrointestinal tract and are involved in gut motility and appetite regulation. Consequently, they are a pharmacological target for anti-obesity drugs (31, 32). 5-HT2AR and 5-HT2CR share nearly 80% sequence homology in their TM regions and have similar pharmacological features (33). The subfamilies show differences in their structures in the ICL2. The differences observed between 5-HT2BR and 5-HT2AR, particularly in the outward shifts of TM5 and TM6 and the inward shift of TM3, highlight the structural divergence between these two receptors. Additionally, the longer ECL2 in 5-HT2BR, containing six additional residues, results in a shorter TM4 compared to 5-HT2AR, influencing the conformation of F5.38 and contributing to the distinctive side-extended cavity formation in 5-HT2AR (34).

The 5-HT2AR is notable for its significance in regulating essential brain processes (35). Psychedelic substances, renowned for their strong psychoactive effects, are thought to primarily interact with the 5-HT2AR (5). The crystal structures of 5-HT2AR and antipsychotics, risperidone, zotepine and lumateperone, complex exhibit the interaction of these ligands with I1633.40 and F3326.44 in the PIF motif and the toggle switch W3366.48 on the lower part of the ligand-binding pocket, which stabilizes the receptor in its inactive state (Fig. 1B). Additionally, located between TM4 and TM5 is a side-extended cavity that connects the orthosteric site and the plasma membrane, facilitating interaction with ligands. This cavity is stabilized by G2385.42 residue present at the entrance of the cavity. The residues on ECL2 adopt different conformations upon binding to these ligands and the entrance of the ligand binding pocket is wider in risperidone bound structure compared to zotepine bound structure. The ligands’ binding sites overlap with those of inverse agonists in other receptors (ritanserin in 5-HT2CR, risperidone in D2R and doxepin in H1R). The structure of risperidone-bound 5-HT2AR is similar to that of the 5-HT2CR bound to ritanserin, but 5-HT2AR has a unique side-extended cavity near the OBP. Additionally, 5-HT2AR differs from D2R in ECL1 and ECL2 conformation, suggesting a potential for designing selective 5-HT2AR antagonists. The structures of serotonin and psilocin-bound 5-HT2AR showed glycerol groups of monoolein inserted deep into the OBP, which led to the activation of 5-HT2AR. The glycine residue at position 5.42 in the OBP is conserved only in the 5-HT2 family, which allows for the extension of the side extended pocket (SEP) from the OBP. In 5-HT2BR and 5-HT2CR, phenylalanine disrupts the SEP despite the conserved glycine. Lipids did not induce robust G protein signaling in 5-HT receptors lacking conserved glycine. These findings explain the lipid modulation of 5-HT2AR signaling (36-38).

The structure of LSD and ergotamine-bound 5-HT2BR demonstrated the mechanisms responsible for G protein and β-arrestin signaling (Fig. 1B). LSD bound structure showed that residue I453 and L464 in the C-tail are important for β-arrestin-1 recruitment. β-arrestin-1 coupling of 5-HT2BR is mediated by hydrophobic and electrostatic interactions between the finger loop of β-arrestin-1 and the cytoplasmic core of 5-HT2BR. Additionally, the hydrophobic interactions between I16134.51 residue of 5-HT2BR and the β-arrestin-1 residues play a significant role in β-arrestin-1 recruitment by 5-HT2BR. The transducer coupling mode of 5-HT2BR is determined by residue N3848.47 present at helix 8. In Gq bound state it forms a hydrogen bond with α5 residue N2445.22 of Gq, whereas the residue rotates 90° in the β-arrestin-1 state with no significant interaction (17). Notably, LSD-bound 5-HT2BR showed that the diethylamide moiety of LSD interacts with TM3 and TM7 within the EBP and the recognition of LSD in this region was stereoselective. Only the (S,S)-azetidide stereoisomer of LSD showed LSD’s potent agonism (39). A comparison of the structures of 5-HT2BR bound to lisuride and LSD showed differences in the EBP, indicating that the interaction of ligands with TM7, specifically with L3627.35, triggers a supplementary mechanism of agonist activation through the EBP (40). Another important residue for receptor activation is T1403.37 and A2255.46, which form hydrogen bond and van der walls interactions, respectively, with the indole group of ergolines. Methylergonovine acts as an agonist at 5-HT2BR, whereas methysergide that differs from methylergonovine in one methyl group acts as an antagonist due to the lack of interactions with the T1403.37 and A2255.46 residues (40).

The structures of 5-HT2CR have been solved in complex with agonist ergotamine, lorcaserin, and psilocin and inverse agonist ritanserin. Compared to the active ERG-bound structure, ritanserin binds approximately one helical turn deeper into the TM bundle forming interactions with the toggle switch and PIF motif and prevents the conformational changes in these microswitches as observed in inverse agonists bound 5-HT2AR (38). The structures of different isoforms of 5-HT2CR and lorcaserin and psilocin complex revealed that the active state structure of 5-HT2CR is stabilized by a hydrogen bond network in the ICL2 region of the receptor (Fig. 2B). Such interactions favored the binding of the α5 helix of Gαq to the receptor and thus activating the receptor (41).


The 5-HT5 receptor subfamily consists of two receptors, 5-HT5A and 5-HT5B. The two receptors have a 69% similarity in their amino acid composition and a 23-34% similarity with the remaining 5-HT receptors (42). 5-HT5BR are specific to the brain and are not present in humans (43). 5-HT5AR are mainly located in the brain regions responsible for memory and learning, and they play a role in neurotransmitter release and synaptic plasticity (44). The human 5-HT5AR receptor remains largely mysterious and poorly understood compared to other serotonin receptors (45).

Four structures of 5-HT5AR have been determined in the presence of two full agonists, 5-CT and methylergometrine, one partial agonist lisuride and antagonist AS2674723 (Table 1, Fig. 1C). Compared to the 5-CT and methylergometrine bound 5-HT5AR-Gi structure, lisuride forms weaker interactions with TM3 and TM6 resulting in the pan agonism of lisuride. The inactive state structure of 5-HT5AR bound to antagonist AS2674723 revealed that the tetrahydroisoquinoline ring, guanidine group, and a trifluorophenyl ring in the AS2674723 interacts with the OBP and EBP by hydrophobic interactions, π−π interactions and salt bridge. Particularly, the formation of a salt bridge by guanidine with E1012.65 is accompanied by a shift in the extracellular end of TM2 compared to the active state structures. Two less conserved residues in the 5-HT receptors, the L3247.39 and E1012.65, play a role in determining the selectivity of AS2674723 for 5-HT5AR. 5-HT7R has aspartate in place of glutamate at position 2.65 which can form similar electrostatic interactions with the guanidine group of AS2674723, explaining the off-target effect of this ligand for 5-HT7R. The inactive 5-HT5AR structure also showed a kinked structure in the intracellular end of TM5, which may inhibit signaling activation through the blockage of TM6 movement. This type of interface is present only in 5-HT1ER, 5-HT1FR, 5-HT5AR and 5-HT7R among all serotonin receptors offering potential opportunities for designing inactive state structures of these receptors (46, 47).


5-HT4R are found in various regions of the CNS and peripheral tissues, including GIT, heart and smooth muscle cells. In the GIT, they regulate motility, secretion and visceral sensitivity. Consequently, they are therapeutic targets for 5-HT4R agonists for managing gastrointestinal disorders like irritable bowel syndrome (IBS) and constipation (48). In contrast, 5-HT6R are primarily found in the CNS, and therefore are an interesting target for therapeutic agents for enhancing cognitive function (49). The 5-HT7R have a broader distribution in the CNS, encompassing regions such as the spinal cord, hippocampus and thalamus. These regulate circadian rhythm, mood and cognitive processes, making them potential targets for treating conditions like depression, anxiety, schizophrenia and cognitive impairments (50). 5-HT6R and 5-HT7R are the targets of several typical and atypical antipsychotics (51).

The cryo-EM structures of 5-HT4/6/7 receptors and ligands complex reveal differences in ECL2 conformation (Fig. 2C). A structural study of 5-HT7R highlighted the significance of the 6.55 residue in determining ligand selectivity. This residue has a smaller side chain in 5-HT7/1A/1B/1D receptors, whereas other 5-HT receptors have a bulkier side chain. A comparison of 5-HT7R and 5-HT1ER structures suggests that the bulkier E3116.55 in 5-HT1E may lead to unfavorable interactions with the amide group of 5-CT, resulting in reduced binding affinity for 5-HT1ER. Additionally, a comparison of 5-HT4R, 5-HT6R and other serotonin-bound receptors revealed some unique residues in their ligand-binding pockets such as residues at positions 3.28, 5.46 and 6.55 in 5-HT4/6/1A/1D receptors. For instance, 5-HT4R has a unique R963.28 residue that is involved in a hydrogen-bonding network, 5-HT6R has a distinctive T1965.46 residue that forms a hydrogen bond with indole nitrogen of serotonin and 5-HT1AR lacks a polar group at position 6.55 that are present in 5-HT4R, 5-HT6R and 5-HT1DR. These unique binding site residues is a potential for optimizing receptor selectivity in drug design (14).


The ligand binding region of 5-HT receptors is formed by residues from TM3, TM5, TM6, TM7 and ECL2. The OBP is located deep within the core of the seven TM structure and is a primary site where ligands bind to activate the receptor (52). Analyses of all human 5-HT GPCR sequences demonstrated that the residues found within the OBP exhibit a higher level of conservation suggesting that there is likely an evolutionary drive to maintain the structural integrity of the OBP, which is crucial for the recognition of the native ligand, 5-HT (16, 53). The conserved Asp3.32 residue within the TM3 interacts with the amine-containing ligands through a salt bridge (16, 25, 34, 38). Moreover, within the binding pocket of all 5-HT receptor family, there are conserved aromatic residues W6.48, F6.51, F6.52 and Y7.43 (Fig. 2). These residues create a confined hydrophobic crevice that facilitates crucial π–π stacking interactions with ligands containing aromatic ring structures (6, 54). On the other hand, the EBP is a supplementary site situated close to the receptor’s extracellular entrance. Although not directly involved in ligand binding and activation, it can modulate ligand selectivity and receptor function. Compared to the OBP, the residues in the EBP are less conserved and vary among the receptor subtypes, thus allowing for receptor-specific interactions with the ligands (6). The superimposition of all ligands bound 5-HT receptors showed that the ligands bind to the different pockets. The OBP ligands are mostly the tryptamine family such as 5-HT and 5-CT. The ligands aripiprazole and donitriptan have quite different characters. Both ligands share the same OBP, but they bind different EBP (Fig. 2). The residues 6.55 and 6.58 may affect the ligand specificity and binding pose with the two ligands.


The G-protein coupling mode of 5-HT receptor family is similar to class A GPCRs involving the rearrangement of residues in the conserved motifs and microswitches (55). In the active state of the GPCRs, the binding of agonist induces an outward shift of the cytoplasmic end of TM6. This conformational shift is caused by the rearrangement of residues in the PIF and DRY motifs and the downward press of W6.48 in the toggle switch, resulting in the breaking of the conserved salt bridge between TM3 and TM6. Additionally, TM7 undergoes an inward movement, opening the cytoplasmic pocket for binding to Gi protein (24). Despite elucidating the structures of all the 12 5-HT receptors, our knowledge regarding the specific G protein preferences of these receptors is still lacking due to insufficient research in this area. To understand the variations in G protein interactions, we conducted a superimposition of the 12 solved 5-HT receptor structures using the structure of the receptor as a template. This allowed us to identify and compare the differences among the structures in their interactions with G proteins. The G protein demonstrates a rotation around the axis of the I residue (G.H5.15), resulting in more significant rotations of both the ɑ5 helix and ɑN helix (Fig. 3A). Afterward, we conducted a deeper examination of the positioning of the ɑN helix in different G proteins, including Gi, Gs and Gq proteins. Surprisingly, we found that each G protein could be classified based on the location of its ɑN helix. Specifically, the Gq subunit’s ɑN helix was positioned on the right side; counterclockwise part in Fig. 3A, the Gi subunit’s helix was in the middle, and the Gs subunit’s helix was situated on the left and bottom, the clockwise part in Fig. 3B. The salt bridge between R3.50 and D3.49 in the DRY motif determines the functional selectivity of the receptor for β-arrestin signaling. In the crystal structure of 5-HT1BR, the salt bridge between R3.50 and D3.49 is broken, but the bond is preserved in 5-HT2BR suggesting that ergolines bound to these receptors showed characteristics of an intermediate active state for the 5-HT1BR and β-arrestin biased activation state for 5-HT2BR (16). The conserved residues within the TM5 and TM6 in class A GPCRs determine the receptor’s selectivity towards G proteins. 5-HT4R, which can couple to both Gs and Gi showed a noticeable change in the intracellular end of TM5, which is extended by 12 residues in the Gs-coupled state in contrast to the Gi-coupled state (14).


The structural features of the 5-HT family, in complex with various ligands and effectors provide valuable insights into their ligand recognition and downstream signaling pathways. Conserved residues within their TM domains play a crucial role in ligand binding and interaction with G proteins. Diversity in extracellular loops, particularly ECL2, suggests potential variations in ligand selectivity and receptor function among subtypes. The OBP and EBP modulate ligand selectivity and receptor function, while specific G protein coupling profiles determine intracellular responses. Additionally, arrestins’ involvement adds complexity to GPCR regulation. 5-HT receptors have implications for mental health disorders and neurological diseases (56). However, despite considerable progress in studying the structure of GPCRs, specific agonists and antagonists for subfamilies are lacking. Consequently, during treatment, there is polypharmacology and side effects. Therefore, further research on the structure of 5-HT receptors is needed to gain a comprehensive understanding of their function and enable the development of novel therapeutics that are highly selective to specific receptor subtypes based on their structural characteristics.


This work was supported by the National Research foundation of Korea (NRF) grant funded by the Korea government (MSIT) (RS-2023-00214187). This work was supported by the Yonsei University Research Fund of 2022 (2022-22-0138).


The authors have no conflicting interests.

Fig. 1. Structures of all 12 G-protein coupled serotonin receptors. Cryo-EM maps of (A) 5-HT1 family: aripiprazole bound 5-HT1A (PDB ID: 7E2Z), donitriptan bound 5-HT1B (PDB ID: 6G79), 5-HT bound 5-HT1D (PDB ID: 7E32), BRL-54443 bound 5-HT1E (PDB ID: 7E33), Lasmiditan bound 5-HT1F (PDB ID: 7EXD), (B) 5-HT2 family: 25-CN-NBOH bound 5-HT2A (PDB ID: 6WHA), LSD bound 5-HT2B (PDB ID: 7SRR), LSD bound 5-HT2B in complex with β-arrestin (PDB ID: 7SRS), Lorcaserin bound 5-HT2C (PDB ID: 8DPI) and (C) 5-HT4/5/6/7 family: 5-HT bound 5-HT4 (PDB ID: 7XT8), 5-CT bound 5-HT5 (PDB ID: 7UM5), 5-HT bound 5-HT6 (PDB ID: 7XTB), and 5-CT bound 5-HT7 (PDB ID: 7XTC).
Fig. 2. Structural difference in the ligand binding pocket of all serotonin receptors were superimposed and compared the ligand binding pose in the same direction. Close up view of the ligand binding site of (A) 5-HT1 family: aripiprazole bound 5-HT1A (PDB ID: 7E2Z), donitriptan bound 5-HT1B (PDB ID: 6G79), 5-HT bound 5-HT1D (PDB ID: 7E32), BRL-54443 bound 5-HT1E (PDB ID: 7E33), lasmiditan bound 5-HT1F (PDB ID: 7EXD), (B) 5-HT2 family: 25-CN-NBOH bound 5-HT2A (PDB ID: 6WHA), LSD bound 5-HT2B (PDB ID: 7SRR), lorcaserin bound 5-HT2C (PDB ID: 8DPI) and (C) 5-HT4/5/6/7 family: 5-HT bound 5-HT4 (PDB ID: 7XT8), 5-CT bound 5-HT5 (PDB ID: 7UM5), 5-HT bound 5-HT6 (PDB ID: 7XTB), and 5-CT bound 5-HT7 (PDB ID: 7XTC).
Fig. 3. The binding of G protein and receptor exhibit distinct binding orientations by G protein subunit. (A) Comparison of the Gα conformation among the structures of different G-protein coupled serotonin receptors. The superimposition of G protein using the structure of the serotonin receptor as a template shows the structural difference of the αN helix and α5 helix between G alpha subunits such as Gs, Gi and Gq subunit. (B) Detailed view of the conformation of α helix in complex with serotonin receptors.

Serotonin receptor structure

Serotonin receptor family G protein coupling PDB Method Ligand Reference
Gi/Go 7E2X Cryo-EM Apostate (24)
7E2Y Cryo-EM 5-HT
7E2Z Cryo-EM Aripiprazole
5-HT1B Gi/Go 4IAQ X-ray Dihydroergotamine (25)
4IAR X-ray Ergotamine
5V54 X-ray Methiothepin (27)
6G79 Cryo-EM Donitriptan (26)
7C61 X-ray Ergotamine (57)
5-HT1D Gi/Go 7E32 Cryo-EM 5-HT (24)
5-HT1E Gi/Go 7E33 Cryo-EM BRL-54443
5-HT1F Gi/Go 7EXD X-ray Lasmiditan (29)
5-HT2A Gq 6A93 X-ray Risperidone (36)
6A94 X-ray Zotepine (36)
7WC4 X-ray 5-HT (58)
7WC5 X-ray Psilocin
7WC6 X-ray LSD
7WC7 X-ray Lisuride
7WC8 X-ray Lumateperone
7WC9 X-ray IHCH-7086
6WHA Cryo-EM 25-CN-NBOH (59)
7RAN Cryo-EM (R)-69 (60)
5-HT2B Gq 5TUD X-ray Ergotamine (61)
7TVN X-ray LSD (39)
6DRX X-ray Lisuride (40)
6DRY X-ray Methylergonovine
6DRZ X-ray Methysergide
6DS0 X-ray LY266097
4IB4 X-ray Ergotamine (16)
7SRQ Cryo-EM LSD (17)
5-HT2C Gq 6BQG X-ray Ergotamine (38)
6BQH X-ray Ritanserin
8DPF Cryo-EM Lorcaserin (41)
8DPG Cryo-EM Psilocin
8DPH Cryo-EM Lorcaserin
8DPI Cryo-EM Lorcaserin
5-HT4 Gi 7XTA Cryo-EM 5-HT (14)
Gs 7XT8 Cryo-EM 5-HT
7XT9 Cryo-EM 5-HT
5-HT5A Gi/Go 7UM4 X-ray AS2674723 (47)
7UM5 Cryo-EM 5-CT
7UM6 Cryo-EM Lisuride
7UM7 Cryo-EM Methylergometrine
7X5H Cryo-EM 5-CT (46)
5-HT6 Gs 7XTB Cryo-EM 5-HT (14)
8JLZ Cryo-EM ST1936 (62)
5-HT7 Gs 7XTC Cryo-EM 5-CT (14)

  1. Chun L, Zhang WH and Liu JF (2012) Structure and ligand recognition of class C GPCRs. Acta Pharmacol Sin 33, 312-323.
    Pubmed KoreaMed CrossRef
  2. Fredriksson R, Lagerström MC, Lundin LG and Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63, 1256-1272.
    Pubmed CrossRef
  3. Pin JP, Galvez T and Prézeau L (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 98, 325-354.
    Pubmed CrossRef
  4. Stevens RC, Cherezov V and Katritch V et al (2013) The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov 12, 25-34.
    Pubmed KoreaMed CrossRef
  5. Nichols DE and Nichols CD (2008) Serotonin receptors. Chem Rev 108, 1614-1641.
    Pubmed CrossRef
  6. McCorvy JD and Roth BL (2015) Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther 150, 129-142.
    Pubmed KoreaMed CrossRef
  7. Kroeze WK, Kristiansen K and Roth BL (2002) Molecular biology of serotonin receptors-structure and function at the molecular level. Curr Top Med Chem 2, 507-528.
    Pubmed CrossRef
  8. Berger M, Gray JA and Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60, 355-366.
    Pubmed KoreaMed CrossRef
  9. Roth BL, Sheffler DJ and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3, 353-359.
    Pubmed CrossRef
  10. Rasmussen SG, Choi HJ and Rosenbaum DM et al (2007) Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450, 383-387.
    Pubmed CrossRef
  11. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25, 366-428.
  12. Wang YQ, Lin WW and Wu N et al (2019) Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis. Acta Pharmacol Sin 40, 1138-1156.
    Pubmed KoreaMed CrossRef
  13. Noda M, Higashida H, Aoki S and Wada K (2004) Multiple signal transduction pathways mediated by 5-HT receptors. Mol Neurobiol 29, 31-39.
    Pubmed CrossRef
  14. Huang S, Xu P and Shen DD et al (2022) GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors. Mol Cell 82, 2681-2695.
    Pubmed CrossRef
  15. Freedman NJ and Lefkowitz RJ (1996) Desensitization of G protein-coupled receptors. Recent Prog Horm Res 51, 319-351.
  16. Wacker D, Wang C and Katritch V et al (2013) Structural features for functional selectivity at serotonin receptors. Science 340, 615-619.
    Pubmed KoreaMed CrossRef
  17. Cao C, Barros-Álvarez X and Zhang S et al (2022) Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD. Neuron 110, 3154-3167.
    Pubmed KoreaMed CrossRef
  18. Aznavour N and Zimmer L (2007) MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology 52, 695-707.
    Pubmed CrossRef
  19. Hoyer D, Clarke DE and Fozard JR et al (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46, 157-203.
  20. Sharp T and Barnes NM (2020) Central 5-HT receptors and their function; present and future. Neuropharmacology 177, 108155.
    Pubmed CrossRef
  21. Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
    Pubmed CrossRef
  22. Villaln C, Centurin D, Valdivia L, de Vries P and Saxena PR (2003) Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 1, 71-84.
    Pubmed CrossRef
  23. Bruinvels A, Landwehrmeyer B and Gustafson E et al (1994) Localization of 5-HT1B, 5-HT1Dα, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 33, 367-386.
    Pubmed CrossRef
  24. Xu P, Huang S and Zhang H et al (2021) Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 592, 469-473.
    Pubmed CrossRef
  25. Wang C, Jiang Y and Ma J et al (2013) Structural basis for molecular recognition at serotonin receptors. Science 340, 610-614.
    Pubmed KoreaMed CrossRef
  26. García-Nafría J, Nehmé R, Edwards PC and Tate CG (2018) Cryo-EM structure of the serotonin 5-HT1B receptor coupled to heterotrimeric Go. Nature 558, 620-623.
    Pubmed KoreaMed CrossRef
  27. Yin W, Zhou XE and Yang D et al (2018) Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. Cell Discov 4, 12.
    Pubmed KoreaMed CrossRef
  28. Negro A, Koverech A and Martelletti P (2018) Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res 11, 515-526.
    Pubmed KoreaMed CrossRef
  29. Huang S, Xu P and Tan Y et al (2021) Structural basis for recognition of anti-migraine drug lasmiditan by the serotonin receptor 5-HT1F-G protein complex. Cell Res 31, 1036-1038.
    Pubmed KoreaMed CrossRef
  30. Aznar S and Hervig ME-S (2016) The 5-HT2A serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases. Neurosci Biobehav Rev 64, 63-82.
    Pubmed CrossRef
  31. De Deurwaerdère P, Bharatiya R, Chagraoui A and Di Giovanni G (2020) Constitutive activity of 5-HT receptors: factual analysis. Neuropharmacology 168, 107967.
    Pubmed CrossRef
  32. Leysen J (2004) 5-HT2 receptors. CNS Neurol Disord Drug Targets 3, 11-26.
    Pubmed CrossRef
  33. Berg KA, Harvey JA, Spampinato U and Clarke WP (2008) Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression. Prog Brain Res 172, 287-305.
    Pubmed CrossRef
  34. Kimura KT, Asada H and Inoue A et al (2019) Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine. Nat Struct Mol Biol 26, 121-128.
    Pubmed CrossRef
  35. Zhang G and Stackman RW Jr (2015) The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 6, 225.
    Pubmed KoreaMed CrossRef
  36. Kimura KT, Asada H and Inoue A et al (2019) Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine. Nat Struct Mol Biol 26, 121-128.
    Pubmed CrossRef
  37. Michino M, Beuming T, Donthamsetti P, Newman AH, Javitch JA and Shi L (2015) What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?. Pharmacol Rev 67, 198-213.
    Pubmed KoreaMed CrossRef
  38. Peng Y, McCorvy JD and Harpsøe K et al (2018) 5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology. Cell 172, 719-730.
    Pubmed KoreaMed CrossRef
  39. Wacker D, Wang S and McCorvy JD et al (2017) Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377-389.
    Pubmed KoreaMed CrossRef
  40. McCorvy JD, Wacker D and Wang S et al (2018) Structural determinants of 5-HT2B receptor activation and biased agonism. Nat Struct Mol Biol 25, 787-796.
    Pubmed KoreaMed CrossRef
  41. Gumpper RH, Fay JF and Roth BL (2022) Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors. Cell Rep 40, 111211.
    Pubmed KoreaMed CrossRef
  42. Grailhe R, Grabtree GW and Hen R (2001) Human 5-HT5 receptors: the 5-HT5A receptor is functional but the 5-HT5B receptor was lost during mammalian evolution. Eur J Pharmacol 418, 157-167.
    Pubmed CrossRef
  43. Nelson D (2004) 5-HT5 receptors. CNS Neurol Disord Drug Targets 3, 53-58.
    Pubmed CrossRef
  44. Thomas DR (2006) 5-ht5A receptors as a therapeutic target. Pharmacol Ther 111, 707-714.
    Pubmed CrossRef
  45. Levit Kaplan A, Strachan RT and Braz JM et al (2022) Structure-based design of a chemical probe set for the 5-HT5A serotonin receptor. J Med Chem 65, 4201-4217.
    Pubmed KoreaMed CrossRef
  46. Tan Y, Xu P and Huang S et al (2022) Structural insights into the ligand binding and Gi coupling of serotonin receptor 5-HT5A. Cell Discov 8, 50.
    Pubmed KoreaMed CrossRef
  47. Zhang S, Chen H and Zhang C et al (2022) Inactive and active state structures template selective tools for the human 5-HT5A receptor. Nat Struct Mol Biol 29, 677-687.
    Pubmed KoreaMed CrossRef
  48. Eglen RM, Wong EH, Dumuis A and Bockaert J (1995) Central 5-HT4 receptors. Trends Pharmacol Sci 16, 391-398.
    Pubmed CrossRef
  49. Mitchell ES and Neumaier JF (2005) 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 108, 320-333.
    Pubmed CrossRef
  50. Guseva D, Wirth A and Ponimaskin E (2014) Cellular mechanisms of the 5-HT7 receptor-mediated signaling. Front Behav Neurosci 8, 306.
    Pubmed KoreaMed CrossRef
  51. Roth BL, Craigo SC and Choudhary MS et al (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268, 1403-1410.
  52. Kristiansen K, Kroeze WK and Willins DL et al (2000) A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT2A serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther 293, 735-746.
  53. Katritch V, Cherezov V and Stevens RC (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33, 17-27.
    Pubmed KoreaMed CrossRef
  54. Choudhary MS, Craigo S and Roth BL (1993) A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. Mol Pharmacol 43, 755-761.
  55. Sarkar P, Mozumder S, Bej A, Mukherjee S, Sengupta J and Chattopadhyay A (2021) Structure, dynamics and lipid interactions of serotonin receptors: excitements and challenges. Biophys Rev 13, 101-122.
    Pubmed KoreaMed CrossRef
  56. Naughton M, Mulrooney JB and Leonard BE (2000) A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 15, 397-415.
    Pubmed CrossRef
  57. Miyagi H, Asada H and Suzuki M et al (2020) The discovery of a new antibody for BRIL-fused GPCR structure determination. Sci Rep 10, 11669.
    Pubmed KoreaMed CrossRef
  58. Cao D, Yu J and Wang H et al (2022) Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 375, 403-411.
    Pubmed CrossRef
  59. Kim K, Che T and Panova O et al (2020) Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574-1588.
    Pubmed KoreaMed CrossRef
  60. Kaplan AL, Confair DN and Kim K et al (2022) Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature 610, 582-591.
    Pubmed KoreaMed CrossRef
  61. Ishchenko A, Wacker D and Kapoor M et al (2017) Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody. Proc Natl Acad Sci U S A 114, 8223-8228.
    Pubmed KoreaMed CrossRef
  62. Pei Y, Wen X and Guo SC et al (2023) Structural insight into the selective agonist ST1936 binding of serotonin receptor 5-HT6. Biochem Biophys Res Commun 671, 327-334.
    Pubmed CrossRef

This Article

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Funding Information


Social Network Service